Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in the PRECEPT cohort, an already existing cohort of 806 subjects recruited to participate in the study called, A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Early Parkinson's Disease - (PRECEPT), sponsored by Cephalon and Lundbeck and coordinated by the Parkinson Study Group. The imaging data from this long-term PRECEPT follow-up study will allow us to evaluate the long-term progression of DAT loss in PD, the long-term follow-up of SWEDD subjects, the relationship between long-term clinical and imaging PD outcomes, and the relationship between long-term imaging outcomes and genetic and biochemical biomarkers of PD progression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute for Neurodegenerative Disorders
• Collaborator: United States Department of Defense

Criteria

Inclusion Criteria:

• Subject was a participant in the PRECEPT clinical and imaging study

• Participant must be willing and able to comply with study procedures

• Participant must be willing and able to give informed consent.

Exclusion Criteria:

• The participant has a clinically significant clinical laboratory value and/or medical or psychiatric illness

• The participant has dementia (MMSE≤24)

• Pregnancy